AbbVie Inc. Cost of Revenue
AbbVie Inc. (ABBV) reported Cost of Revenue of $4.29 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-03
- AbbVie Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $4.29B, a 1.27% decline year-over-year.
- AbbVie Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $4.22B, a 5.40% increase year-over-year.
- AbbVie Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $4.55B, a 3.55% increase year-over-year.
- AbbVie Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $5.30B, a 25.93% increase year-over-year.
- AbbVie Inc. cost of goods and services sold for fiscal 2025 was $18.20B, a 7.69% increase from fiscal 2024.
- AbbVie Inc. cost of goods and services sold for fiscal 2024 was $16.90B, a 17.20% decline from fiscal 2023.
- AbbVie Inc. cost of goods and services sold for fiscal 2023 was $20.41B, a 17.23% increase from fiscal 2022.
- AbbVie Inc. cost of goods and services sold for fiscal 2022 was $17.41B, a 0.18% decline from fiscal 2021.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.29B 10-Q · filed 2026-08-03 | $8.51B 10-Q · filed 2026-08-03 | $13.06B derived: sum of 3 quarters · filed 2026-08-03 | $18.36B derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $4.22B 10-Q · filed 2026-05-08 | $8.77B derived: sum of 2 quarters · filed 2026-05-08 | $14.07B derived: sum of 3 quarters · filed 2026-05-08 | $18.42B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $4.55B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $9.86B derived: sum of 2 quarters · filed 2026-02-20 | $14.20B derived: sum of 3 quarters · filed 2026-08-03 | $18.20B 10-K · filed 2026-02-20 |
| 2025-09-30 | $5.30B 10-Q · filed 2025-11-04 | $9.65B derived: sum of 2 quarters · filed 2026-08-03 | $13.65B 10-Q · filed 2025-11-04 | $18.05B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $4.35B 10-Q · filed 2026-08-03 | $8.35B 10-Q · filed 2026-08-03 | $12.74B derived: sum of 3 quarters · filed 2026-08-03 | $16.96B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $4.00B 10-Q · filed 2026-05-08 | $8.40B derived: sum of 2 quarters · filed 2026-05-08 | $12.61B derived: sum of 3 quarters · filed 2026-05-08 | $16.81B derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $4.40B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $8.61B derived: sum of 2 quarters · filed 2026-02-20 | $12.81B derived: sum of 3 quarters · filed 2026-02-20 | $16.90B 10-K · filed 2026-02-20 |
| 2024-09-30 | $4.21B 10-Q · filed 2025-11-04 | $8.41B derived: sum of 2 quarters · filed 2025-11-04 | $12.51B 10-Q · filed 2025-11-04 | $18.21B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-06-30 | $4.20B 10-Q · filed 2025-08-04 | $8.30B 10-Q · filed 2025-08-04 | $14.00B derived: sum of 3 quarters · filed 2026-02-20 | $20.48B derived: sum of 4 quarters · filed 2026-02-20 |
| 2024-03-31 | $4.09B 10-Q · filed 2025-05-09 | $9.80B derived: sum of 2 quarters · filed 2026-02-20 | $16.28B derived: sum of 3 quarters · filed 2026-02-20 | $20.52B derived: sum of 4 quarters · filed 2026-02-20 |
| 2023-12-31 | $5.70B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $12.19B derived: sum of 2 quarters · filed 2026-02-20 | $16.43B derived: sum of 3 quarters · filed 2026-02-20 | $20.41B 10-K · filed 2026-02-20 |
| 2023-09-30 | $6.49B 10-Q · filed 2024-11-04 | $10.72B derived: sum of 2 quarters · filed 2024-11-04 | $14.71B 10-Q · filed 2024-11-04 | $18.88B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-06-30 | $4.24B 10-Q · filed 2024-08-07 | $8.23B 10-Q · filed 2024-08-07 | $12.40B derived: sum of 3 quarters · filed 2025-02-14 | $17.42B derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-03-31 | $3.99B 10-Q · filed 2024-05-03 | $8.16B derived: sum of 2 quarters · filed 2025-02-14 | $13.18B derived: sum of 3 quarters · filed 2025-02-14 | $17.35B derived: sum of 4 quarters · filed 2025-02-14 |
| 2022-12-31 | $4.17B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $9.19B derived: sum of 2 quarters · filed 2025-02-14 | $13.36B derived: sum of 3 quarters · filed 2025-02-14 | $17.41B 10-K · filed 2025-02-14 |
| 2022-09-30 | $5.02B 10-Q · filed 2023-11-06 | $9.19B derived: sum of 2 quarters · filed 2023-11-06 | $13.24B 10-Q · filed 2023-11-06 | $17.56B derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $4.17B 10-Q · filed 2023-08-07 | $8.22B 10-Q · filed 2023-08-07 | $12.54B derived: sum of 3 quarters · filed 2024-02-20 | $16.93B derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $4.05B 10-Q · filed 2023-05-05 | $8.37B derived: sum of 2 quarters · filed 2024-02-20 | $12.76B derived: sum of 3 quarters · filed 2024-02-20 | $17.29B derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $4.32B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $8.71B derived: sum of 2 quarters · filed 2024-02-20 | $13.23B derived: sum of 3 quarters · filed 2024-02-20 | $17.45B 10-K · filed 2024-02-20 |
| 2021-09-30 | $4.39B 10-Q · filed 2022-11-04 | $8.91B derived: sum of 2 quarters · filed 2022-11-04 | $13.13B 10-Q · filed 2022-11-04 | $17.81B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-06-30 | $4.52B 10-Q · filed 2022-08-04 | $8.74B 10-Q · filed 2022-08-04 | $13.42B derived: sum of 3 quarters · filed 2023-02-17 | $18.47B derived: sum of 4 quarters · filed 2023-02-17 |
| 2021-03-31 | $4.21B 10-Q · filed 2022-05-06 | $8.90B derived: sum of 2 quarters · filed 2023-02-17 | $13.95B derived: sum of 3 quarters · filed 2023-02-17 | $17.66B derived: sum of 4 quarters · filed 2023-02-17 |
| 2020-12-31 | $4.68B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $9.73B derived: sum of 2 quarters · filed 2023-02-17 | $13.45B derived: sum of 3 quarters · filed 2023-02-17 | $15.39B 10-K · filed 2023-02-17 |
| 2020-09-30 | $5.05B 10-Q · filed 2021-11-02 | $8.76B derived: sum of 2 quarters · filed 2021-11-02 | $10.70B 10-Q · filed 2021-11-02 | $12.71B derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-06-30 | $3.71B 10-Q · filed 2021-08-02 | $5.65B 10-Q · filed 2021-08-02 | $7.66B derived: sum of 3 quarters · filed 2022-02-18 | $9.58B derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-03-31 | $1.94B 10-Q · filed 2021-05-07 | $3.95B derived: sum of 2 quarters · filed 2022-02-18 | $5.87B derived: sum of 3 quarters · filed 2022-02-18 | $7.69B derived: sum of 4 quarters · filed 2022-02-18 |
| 2019-12-31 | $2.01B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $3.93B derived: sum of 2 quarters · filed 2022-02-18 | $5.75B derived: sum of 3 quarters · filed 2022-02-18 | $7.44B 10-K · filed 2022-02-18 |
| 2019-09-30 | $1.92B 10-Q · filed 2020-11-04 | $3.74B derived: sum of 2 quarters · filed 2020-11-04 | $5.43B 10-Q · filed 2020-11-04 | $7.46B derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-06-30 | $1.82B 10-Q · filed 2020-08-04 | $3.51B 10-Q · filed 2020-08-04 | $5.54B derived: sum of 3 quarters · filed 2021-02-19 | $7.37B derived: sum of 4 quarters · filed 2021-02-19 |
| 2019-03-31 | $1.69B 10-Q · filed 2020-05-08 | $3.72B derived: sum of 2 quarters · filed 2021-02-19 | $5.55B derived: sum of 3 quarters · filed 2021-02-19 | $7.49B derived: sum of 4 quarters · filed 2021-02-19 |
| 2018-12-31 | $2.02B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $3.86B derived: sum of 2 quarters · filed 2021-02-19 | $5.79B derived: sum of 3 quarters · filed 2021-02-19 | $7.72B 10-K · filed 2021-02-19 |
| 2018-09-30 | $1.83B 10-Q · filed 2019-11-06 | $3.77B derived: sum of 2 quarters · filed 2019-11-06 | $5.70B 10-Q · filed 2019-11-06 | $7.98B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | $1.93B 10-Q · filed 2019-08-05 | $3.86B 10-Q · filed 2019-08-05 | $6.14B derived: sum of 3 quarters · filed 2020-02-21 | $7.76B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | $1.93B 10-Q · filed 2019-05-03 | $4.21B derived: sum of 2 quarters · filed 2020-02-21 | $5.82B derived: sum of 3 quarters · filed 2020-02-21 | |
| 2017-12-31 | $2.28B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $3.90B derived: sum of 2 quarters · filed 2020-02-21 | $7.04B 10-K · filed 2020-02-21 | |
| 2017-09-30 | $1.62B 10-Q · filed 2018-11-07 | $4.76B 10-Q · filed 2018-11-07 | ||
| 2016-12-31 | $5.83B 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |